Study of YK012 for relapsed or refractory B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug, YK012, for people with a certain kind of B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not gotten better after standard therapies. It aims to see if the drug is safe and works against these leukemia cells that have the CD19 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell acute lymphoblastic leukemia (B-ALL) with the CD19 marker on the cells.
- Your leukemia has not responded to standard treatment, came back within 12 months, relapsed after a stem cell transplant, or if Philadelphia chromosome-positive, you have tried at least one TKI without success.
- At least 5% of the cells in your bone marrow are leukemia cells (blasts).
- Your major organs (like heart, liver, and kidneys) are working well enough, and you have adequate blood counts.
- You have not had recent chemotherapy, radiation, or other cancer treatments (check specific timeframes).
- You do not have active leukemia spread to your brain or spinal cord, active serious infections, or uncontrolled heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This early study tests MK-1045 in people with precursor B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did not respond to earlier treatment. It may help shrink leukemia and improve remission in patients with limited options.
This trial tests a new drug called CC312 for people with B-cell blood cancers that have come back or stopped responding to treatment. CC312 is designed to target CD19 on cancer cells, and the study checks if it is safe and how the body handles it.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.